# Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

> **NCT00814086** · PHASE1 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 23 (actual)

## Conditions studied

- Chemotherapeutic Agent Toxicity
- Endometrial Adenocarcinoma
- Fallopian Tube Carcinoma
- Gastrointestinal Complication
- Malignant Ovarian Mixed Epithelial Tumor
- Neurotoxicity Syndrome
- Ovarian Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Primary Peritoneal Carcinoma
- Stage II Ovarian Cancer
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer
- Undifferentiated Ovarian Carcinoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00814086
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-07
- **Final completion:** —
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00814086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00814086, "Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00814086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*